Figure 1From: Long term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14.18 or oral metronomic chemotherapy Treatment scheme (for details of N1, N2, N5, N6, N7, D1, and D2 see 'Methods' text, C = choice, R = randomization, ASCT = myeloablative chemotherapy with autologous stem cell transplant, AB = antibody ch14.18).Back to article page